Analysts See $-0.10 EPS for Heat Biologics Inc (HTBX)

August 11, 2017 - By Stephen Andrade

 Analysts See $ 0.10 EPS for Heat Biologics Inc (HTBX)
Investors sentiment decreased to 1.4 in Q4 2016. Its down 1.27, from 2.67 in 2016Q3. It worsened, as 1 investors sold Heat Biologics Inc shares while 4 reduced holdings. 2 funds opened positions while 5 raised stakes. 962,174 shares or 104.60% more from 470,276 shares in 2016Q3 were reported.
Wells Fargo Mn has 231 shares for 0% of their portfolio. Creative Planning invested 0% in Heat Biologics Inc (NASDAQ:HTBX). Morgan Stanley holds 9,796 shares. Vanguard Group reported 254,354 shares. Geode Capital Mgmt Limited Liability Co holds 0% in Heat Biologics Inc (NASDAQ:HTBX) or 79,837 shares. Art Lc has invested 0% in Heat Biologics Inc (NASDAQ:HTBX). Citadel Advisors Llc stated it has 29,367 shares. Royal Bancshares Of Canada accumulated 1,035 shares. Franklin Street Inc Nc owns 70,500 shares for 0.01% of their portfolio. Oxford Asset Mngmt owns 320,951 shares or 0.01% of their US portfolio. Blackrock Fund Advisors reported 2,372 shares stake. Moreover, Kcg Holdg has 0% invested in Heat Biologics Inc (NASDAQ:HTBX). Goldman Sachs Group Inc Inc Inc has 17,323 shares for 0% of their portfolio. Financial Bank Of America De accumulated 2 shares or 0% of the stock. Blackrock Ltd Com has 2,991 shares.

Wall Street await Heat Biologics Inc (NASDAQ:HTBX) to release earnings on August, 21. Analysts forecast earnings per share of $-0.10, up exactly $0.07 or 41.18 % from 2014’s $-0.17 EPS. After posting $-0.12 EPS for the previous quarter, Heat Biologics Inc’s analysts now forecast -16.67 % EPS growth. The stock decreased 0.99% or $0.005 on August 10, reaching $0.49. About shares traded. Heat Biologics Inc (NASDAQ:HTBX) has risen 35.57% since August 11, 2016 and is uptrending. It has outperformed by 18.87% the S&P500.

Heat Biologics Inc (NASDAQ:HTBX) Ratings Coverage

Among 4 analysts covering Heat Biologics (NASDAQ:HTBX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heat Biologics had 6 analyst reports since September 1, 2015 according to SRatingsIntel. Noble Financial initiated Heat Biologics Inc (NASDAQ:HTBX) rating on Friday, January 8. Noble Financial has “Buy” rating and $16.0 target. Noble Financial maintained the shares of HTBX in report on Wednesday, June 7 with “Buy” rating. The firm has “Speculative Buy” rating by Cantor Fitzgerald given on Thursday, February 4. The firm has “Buy” rating given on Thursday, September 3 by H.C. Wainwright. The stock has “Buy” rating by Roth Capital on Monday, June 20. Cantor Fitzgerald maintained the shares of HTBX in report on Tuesday, September 1 with “Buy” rating.

Heat Biologics, Inc. is a development-stage firm focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The company has market cap of $17.46 million. The Firm is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). It currently has negative earnings. Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.